NCT06259162 LAG3 Expression in Triple Negative Breast Cancer
| NCT ID | NCT06259162 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Triple Negative Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 128 participants |
| Start Date | 2022-11-18 |
| Primary Completion | 2025-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 128 participants in total. It began in 2022-11-18 with a primary completion date of 2025-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Eligibility Criteria
Inclusion Criteria: * Planned neoadjuvant chemotherapy * Triple negative breast cancer Exclusion Criteria: * HER2-positive breast cancer * Hormone receptor positive breast cancer
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06259162 clinical trial?
This trial is open to female participants only, studying Triple Negative Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06259162 currently recruiting?
Yes, NCT06259162 is actively recruiting participants. Contact the research team at jyeon25@skku.edu for enrollment information.
Where is the NCT06259162 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06259162 clinical trial?
NCT06259162 is sponsored by Samsung Medical Center. The trial plans to enroll 128 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.